Swedish Orphan Biovitrum
Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden. In 2020 it had a revenue of SEK 15,261million and 1,509 employees.
Revenue(RF), mln.USD
9
Assets(RF), mln.USD
4
Capital(RF), mln.USD
1
Staff(RF), 2021
27
Glob.Revenue, mln.USD
2085
The Company Statement
April 29, 2025
Received revenues in Russia in 2021-2023, there is no any official announcement. On April 28, 2025 the Ministry of Health held the first meeting in 2025 of the commission for the formation of lists of vital drugs (VED) and 14 high-cost nosologies (HCN). The commission also included pegcetacoplan (Empaveli from Swedish Orphan Biovitrum AB) in the list of VED.
| April 29, 2025 | Only two drugs out of eight proposed were added to the list of vital and essential drugs — details of the event |
All company names used on this web page are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.
Company statements and statistical data are collected from open sources and official registers according to the methodology of the KSE Institute.
Scanner